A Phase 1b, Open-label Study of LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 27 Jul 2017
At a glance
- Drugs LY 2510924 (Primary) ; Cytarabine; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 10 May 2016 Planned primary completion date changed from 1 Jul 2021 to 1 May 2021.
- 10 May 2016 Status changed from not yet recruiting to recruiting.
- 04 Apr 2016 Planned primary completion date changed from 1 Mar 2021 to 1 Jul 2021 as reported by ClinicalTrials.gov record.